Palatin Technologies, Inc. (NYSEAMERICAN:PTN) gapped up prior to trading on Friday . The stock had previously closed at $1.15, but opened at $1.20. Palatin Technologies shares last traded at $1.23, with a volume of 4787017 shares changing hands.
Several equities research analysts have recently commented on the company. TheStreet raised Palatin Technologies from a “d” rating to a “c-” rating in a report on Thursday, March 29th. HC Wainwright assumed coverage on Palatin Technologies in a report on Friday. They issued a “buy” rating and a $5.00 price objective for the company. One analyst has rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. Palatin Technologies currently has a consensus rating of “Buy” and a consensus target price of $3.44.
Palatin Technologies (NYSEAMERICAN:PTN) last announced its quarterly earnings results on Monday, February 12th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.19. Palatin Technologies had a return on equity of 155.80% and a net margin of 28.55%. The business had revenue of $10.61 million during the quarter. During the same period in the prior year, the business earned ($0.06) EPS.
ILLEGAL ACTIVITY NOTICE: “Palatin Technologies (PTN) Shares Gap Up to $1.20” was reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3340856/palatin-technologies-ptn-shares-gap-up-to-1-20.html.
Palatin Technologies Company Profile
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company's principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD).
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.